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Abstract
Background: Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc
interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among
clinical trials. We performed a systematic review and meta-analysis to obtain a better understanding in the risk of QTc
interval prolongation among cancer patients administered vandetanib.
Methodology and Principal Findings: Eligible studies were phase II and III prospective clinical trials that involved cancer
patients who were prescribed vandetanib 300 mg/d and that included data on QTc interval prolongation. The overall
incidence and risk of QTc interval prolongation were calculated using random-effects or fixed-effects models, depending on
the heterogeneity of the included studies. Nine trials with 2,188 patients were included for the meta-analysis. The overall
incidence of all-grade and high-grade QTc interval prolongation was 16.4% (95% CI, 8.1–30.4%) and 3.7% (8.1–30.4%),
respectively, among non-thyroid cancer patients, and 18.0% (10.7–28.6%) and 12.0% (4.5–28.0%), respectively, among
thyroid cancer patients. Patients with thyroid cancer who had longer treatment duration also had a higher incidence of
high-grade events, with a relative risk of 3.24 (1.57–6.71), than patients who had non-thyroid cancer. Vandetanib was
associated with a significantly increased risk of all-grade QTc interval prolongation with overall Peto odds ratios of 7.26
(4.36–12.09) and 5.70 (3.09–10.53) among patients with non-thyroid cancer and thyroid cancer, respectively, compared to
the controls.
Conclusions/Significance: Treatment with vandetanib is associated with a significant increase in the overall incidence and
risk of QTc interval prolongation. Different cancer types and treatment durations may affect the risk of developing high-
grade QTc interval prolongation.
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Introduction
Vandetanib is a multikinase inhibitor that is currently under
assessment for the treatment of a number of solid tumours. It
targets key signalling pathways in cancer by inhibiting vascular
endothelial growth factor receptor (VEGFR)-dependent tumour
angiogenesis, and epidermal growth factor receptor (EGFR), and
rearranged during transfection (RET)-dependent tumour cell
proliferation and survival [1,2].
Clinical benefits from the administration of vandetanib single
agent were observed in a phase II clinical trial, and durable
objective partial responses and disease control were observed
among patients with advanced or metastatic hereditary medullary
thyroid cancer (MTC) [3]. A phase III randomised controlled trial
(ZETA) also demonstrated a 54% reduction in the risk of disease
progression among MTC patients treated with vandetanib
compared to placebo [4]. In April 2011, the U.S. Food and Drug
Administration (FDA) approved vandetanib as an orphan drug
that could be used to treat MTC unsuitable for surgical resection
or metastatic MTC [5].
The efficacy of vandetanib was also observed in the treatment of
patients with advanced non-small-cell lung cancer (NSCLC) when
concomitantly administered with docetaxel [6]. Compared with
gefitinib, vandetanib also demonstrated significant prolongation of
progression free survival (PFS) [7]. An open-label phase II study
(ZACTHYF) that assessed the benefit of vandetanib for patients
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cancer also showed significantly improved PFS compared with
placebo (11.0 months vs. 5.8 months) [8]. The number of trials
evaluating the benefit of vandetanib for the treatment of colorectal
cancer [9], prostate cancer [10], hepatocellular carcinoma [11],
and many other cancers has recently increased.
However, as with many other therapeutic drugs, vandetanib is
associated with substantial side effects. Diarrhoea, nausea, rash,
and hypertension are the most commonly reported adverse events
when patients are prescribed vandetanib treatment. QTc interval
prolongation is a major adverse effect that has been noted in trials;
it is associated with a high risk of ventricular arrhythmias (e.g.,
torsade de pointes [TdP], syncope, and sudden death) [12,13].
Thus, it is essential that doctors as well as patients receiving
vandetanib therapy recognize and manage the risks for QTc
interval prolongation.
Nevertheless, the incidence of QTc interval prolongation varies
across clinical trials, and ranges from 5.1% to 44.4% [14,15]; the
overall risk of QTc interval prolongation in the patients compared
with that in controls is unclear because of the limited sample sizes
in each trial. Therefore, we sought to fully investigate the




We searched the Pubmed (data from 1966 to April 2011),
Embase (data from 1980 to April 2011) and the Cochrane Library
electronic databases. Keywords included in the search were
‘vandetanib’, ‘ZD6474’, ‘cancer’, and ‘QTc’. The search was
restricted to clinical trials and articles published in English.
Proceedings for the annual meetings of the American Society of
Clinical Oncology (ASCO) and the European Society of Medical
Oncology (ESMO) (from 2001 to April 2011) were searched
manually using the same keywords. Additionally, we searched the
clinical trial registration website (http://www.ClinicalTrials.gov)
to obtain information on the registered randomised controlled
trials (RCTs). We also reviewed the reference lists of the original
and review articles to identify relevant studies.
Study selection and data collection
Two reviewers (JJZ and SQW) independently assessed the
eligibility of the articles and abstracts identified by the search, and
discrepancies were resolved by consensus. Since the daily dose of
vandetanib approved by the FDA is 300 mg/d [5], we assessed
the risk of QTc interval prolongation with vandetanib at this dose
to ensure clinical significance. Because of the dosage variations
and limited sample sizes in phase I trials, we excluded these trials
from the analysis. Only Phase II and III clinical trials in which
only vandetanib was administered at the defined dose were
included. We analysed studies that fulfilled the following criteria:
prospective clinical trials in patients with cancer; participants
assigned to treatment with only vandetanib at a dosage of
300 mg/d; and availability of safety data related to QTc interval
prolongation.
Data extraction was completed independently by 3 reviewers
(YC, EMK, and LY) who used standardized data-collection forms.
For each study that fulfilled the criteria, we extracted the following
information: first author’s name; year of publication; treatment
arms; number of enrolled patients; number of patients in the
treatment and control groups (when available); and adverse
outcomes of interest (QTc interval prolongation).
Clinical endpoints
QTc interval prolongation was recorded according to version 2
Common Terminology Criteria (CTC) or version 3 of the
Common Terminology Criteria for Adverse Events (CTCAE)
[16]. The upper limit value for QT/QTc interval prolongation
was 0.48 s in version 2 CTC and 0.45 s in version 3 of CTCAE.
Trials that used version 2 criteria to identify QTc interval
prolongation might miss some events since patients whose QTc
interval ranged from 0.45 s to 0.48 s were not recorded. However,
if we only included the trials that used the new criteria,
information would have been missed. Therefore, we categorized
the criteria as follows: grade 1, QTc interval .0.45–0.47 s or
asymptomatic, not requiring treatment; grade 2, QTc interval
.0.47–0.50 s, $0.06 s above baseline or symptomatic, but not
requiring treatment; grade 3, QTc interval .0.50 s or symptom-
atic and requiring treatment; and grade 4, QTc interval .0.5 s
with life-threatening signs or symptoms (e.g., arrhythmia,
congestive heart failure, hypotension, shock, syncope, TdP). We
included all incidences of QTc interval prolongation of grade 1 or
above in our analysis.
Statistical analysis
We used version 2 of the Comprehensive Meta Analysis
programme for all statistical analyses. The data of the number of
patients with all grades and high grades (grade 3 and grade 4) of
QTc interval prolongation and of the number of patients receiving
vandetanib were extracted from the adverse events outcomes. For
each study, we derived the proportion and 95% confidence
interval (CI) of patients with QTc interval prolongation. For
studies with a control group in the same trial, we also calculated
and compared the relative risk (RR) of QTc interval prolongation.
Because thyroid functional disorders can lead to arrhythmia,
which may prolong the QTc interval [17], and because patients
with thyroid cancer have a longer treatment duration, which may
also increase the risk of developing QTc interval prolongation
compared to patients with non-thyroid cancer, we pooled results to
create independent non-thyroid cancer and thyroid cancer groups.
The study quality was assessed using the 5-point scale Jadad score
[18]. A trial with a score of 3 or above was regarded as high
quality.
For the meta-analysis, we used both fixed-effects and random-
effects models. In each meta-analysis, the x
2 and I
2 values were
first calculated to assess the heterogeneity of the included trials
[19]; p,0.10 for the x
2 test and I
2,25% were interpreted as
signifying low-level heterogeneity. When there was no statistically
significant heterogeneity, a pooled effect was calculated using a
fixed-effects model; otherwise, a random-effects model was
employed. To calculate the pooled incidence, an inverse variance
statistical method was used. To calculate the pooled RR, if the
event rate was above 1%, we used the Mantel-Haenszel statistical
method; otherwise, Peto odds ratios (ORs) were used to combine
the RRs when events were rare. In this context, estimates of odds
and risks are nearly identical, and both results can be interpreted
as ratios of probabilities [20]. Funnel plots [21] and Egger’s test
[22] were also employed to assess the probability of publication
bias. A two-tailed p,0.05 was deemed statistically significant.
Role of the funding source
The sponsors of the study had no role in the study design, data
collection, data analysis, data interpretation or in the writing of the
report. The corresponding author had full access to all of the data
in the study and had final responsibility for the decision to submit
the study for publication.
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Flow of included studies
A total of 182 potentially relevant trials with vandetanib were
identified by the search strategy, 173 of which were excluded for
the reasons shown in Figure 1. Nine trials met the inclusion
criteria; 7 were published articles, and the rest were meeting
abstracts. A total of 2,188 patients were available for the meta-
analysis. Six trials were RCTs with a control arm, and 3 were
single-arm trials.
Study characteristics
Table 1 shows the characteristics of the individual trials. The
types of cancer included small-cell lung cancer (SCLC) [23],
advanced NSCLC [7,14,15,24], thyroid cancer [4,8], and breast
cancer [25]. The incidence analysis included all the patients in the
9 trials. Median treatment duration ranged from 1.8 to 24.0
months and median progression-free survival ranged from 1.6 to
27.9 months. For calculation of the RRs, 6 RCTs were pooled;
1,134 patients were assigned to the drug group (vandetanib,
300 mg/d) and 976 were assigned to the control or placebo arms.
Jadad scale was used to assess the quality of included trials.
Overall, five trials had a Jadad score of 5, one scored 4, one scored
3 and two scored 2. Formal critical appraisal of the 9 trials
indicated that the quality was high in 7 trials (Jadad score$3) and
low in two trial (Table 1). One of the trials with a Jadad score of
two was single-armed trial, and another one was a phase 2 cohort
study.
Quantitative data synthesis
Data relating to the incidence of all-grade QTc interval
prolongation among 873 patients in the non-thyroid cancer group
who were enrolled in 6 trials were available for analysis. The
incidence ranged from 5.1 to 44.4%; the lowest incidence was
noted in a phase III erlotinib-controlled randomised trial among
patients with NSCLC, and the highest incidence was observed in a
phase II single-arm trial among patients with breast cancer. The
meta-analysis revealed the heterogeneity of the included studies
(I
2=91.4%, p,0.001). We explored the potential source of
heterogeneity by analysing randomised controlled and non-
Figure 1. Selection process for trials.
doi:10.1371/journal.pone.0030353.g001
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ity existed in the RCTs [7,14,23,24], but not in the non-
randomised trials [15,25]. However, there was no compelling
reason to exclude these trials. Analysis using a random-effects
model revealed an overall incidence of 16.4% (95% CI, 8.1–
30.4%) among non-thyroid cancer patients prescribed vandetanib.
The prediction interval was calculated to be 0.063–0.427
(Figure 2A).
Data relating to high-grade QTc interval prolongation among
patients in the non-thyroid cancer group were available for 250
patients enrolled in 5 trials. The incidence ranged from 0.6% to
5.6%, with the lowest incidence in a phase II gefitinib-controlled
randomised trial among patients with NSCLC, and the highest in
a phase II single-arm trial among patients with breast cancer. The
overall incidence of high-grade QTc interval prolongation among
non-thyroid cancer patients was 3.7% (95% CI, 1.7–7.8%; p for
heterogeneity=0.442, I
2=0.0%), as determined using a fixed-
effects model (Figure 2B).
We further analysed the incidence of QTc interval prolongation
among patients with thyroid cancer. The overall incidence of all-
grade and high-grade QTc interval prolongation was 18.0% (95%
CI, 10.7–28.6%; p for heterogeneity=0.058, I
2=72.2%) and
12.0% (4.5–28.0; p for heterogeneity=0.026, I
2=79.7%), respec-
tively (Figure 3), as determined by a random-effects model.
A difference was detected in the incidence of vandetanib-
associated high-grade QTc interval prolongation (RR, 3.24; 95%
CI, 1.57–6.71) between patients with thyroid cancer and those
with a non-thyroid malignancy. There was no difference in the
incidence of all-grade QTc interval prolongation (RR, 1.10, 0.67–
1.87) between patients with the two types of cancer.
The meta-analysis of the RR for QTc interval prolongation
with vandetanib compared with controls was performed for the
RCTs consisting of patients with both non-thyroid and thyroid
cancer. Four and 3 RCTs were included in the analysis of all-
grade and high-grade QTc interval prolongation, respectively,
among non-thyroid cancer patients. Of the 4 RCTs included in
the analysis of all-grade events, 1 trial used placebo as the control
[23], another used placebo plus paclitaxel and carboplatin [24],
another trial used gefitinib [7], and the final trial used erlotinib
[14]. In all the trials, the incidence of QTc interval prolongation
was low in the control groups (0/53, 0/52, 0/85, and 1/614,
respectively). Since the event rate in the control group of each
trial was lower than 1%, we used Peto one-step ORs. The overall
Peto OR was 7.26 for vandetanib versus control for all-grade
QTc interval prolongation among non-thyroid cancer patients
(95% CI, 4.36–12.09; p for heterogeneity=0.970, I
2=0.0%), as
calculated using a fixed-effects model (Figure 4A). Three RCTs
were analysed for high-grade events [7,23,24]. However, the
event rates in both the treatment and control groups were zero in
2 trials [7,24]. Thus, only 1 trial [23] was included in the meta-
analysis. The overall Peto OR was 5.78 for vandetanib versus
control for high-grade QTc interval prolongation among non-
thyroid cancer patients (0.77–43.27) (Figure 4B). Thus, vande-
tanib was associated with a significantly increased risk of all-
grade QTc interval prolongation among patients with non-
thyroid cancer compared with those who were not assigned
vandetanib.
Two RCTs [4,8] were included in the analysis of all-grade
QTc interval prolongation among thyroid cancer patients, and
one [8] was excluded from the analysis of high-grade events. Both
trials used placebo as a control. The overall Peto OR was 5.70
(95% CI, 3.09–10.53; p for heterogeneity=0.199, I
2=39.5%)
and 3.48 (1.27–9.54) for vandetanib versus control for all-grade
and high-grade QTc interval prolongation, respectively, among
thyroid cancer patients, as calculated using a fixed-effects model
(Figure 5).
No evidence of publication bias was detected for the incidence
or Peto ORs of QTc interval prolongation events (all-grade and
high-grade) by either funnel plots or Egger’s tests (data not shown).
TdP occurred in 1 patient in a phase III erlotinib-controlled
randomised trial; the patient recovered without sequelae after
vandetanib was discontinued.
Table 1. Characteristics of clinical trials and patients included in the meta-analysis.











Aronold(2007) 2 SCLC vandetanib 300 mg/d 53 56.9 1.8 2.7 5
Placebo 54 62.4 3.0 2.8
Heymach(2008) 2 NSCLC vandetanib 300 mg/d 73 63.0 NR 2.9 3
Placebo+PC 52 59.0 NR 5.8
Natale(2009) 2 NSCLC vandetanib 300 mg/d 83 63.0 NR 2.8 5
gefitinib 250 mg/d 85 61.0 NR 2.0
Natale(2011) 3 NSCLC vandetanib 300 mg/d 623 61.0 2.3 NR 5
Erlotinib 150 mg/d 617 61.0 2.2 NR
Miller(2005) 2 Breast cancer vandetanib 300 mg/d 24 50.5 NR 1.6 2
Kiura(2008) 2 NSCLC vandetanib 300 mg/d 18 61.0 NR 3.1 5
Wells(2010) 2 Advanced MTC vandetanib 300 mg/d 30 49.0 18.8 27.9 2
Leboulleux(2010) 2 Advanced DTC vandetanib 300 mg/d 72 63.0 18.9 11.0 4
Placebo 73 63.0 19.5 5.8
Wells(2011) 3 Advanced MTC vandetanib 300 mg/d 231 53.0 24.0 .22.6 5
Placebo 100 53.0 24.0 16.4
NSCLC:non-small-cell lung cancer; SCLC:small-cell lung cancer; PC:paclitaxel and carboplatin; MTC:medullary thyroid cancer; DTC:differentiated thyroid cancer.
doi:10.1371/journal.pone.0030353.t001
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To the best of our knowledge, this is the first meta-analysis to
investigate the overall risk of QTc interval prolongation associated
with vandetanib in cancer patients and to find the differences in
the risk between patients with thyroid cancer and those with a
non-thyroid malignancy. The meta-analysis was based on 9 trials
and 2,188 patients.
We noted that the overall incidence of all-grade and high-grade
QTc interval prolongation with vandetanib (300 mg/day) was
16.4% (95% CI, 8.1%–30.4%) and 3.7% (1.7%–7.8%), respec-
tively, among patients with non-thyroid cancer, and 18.0% (10.7–
28.6%) and 12.0% (4.5–28.0%), respectively, among patients with
thyroid cancer. The prediction interval for the incidence of all-
grade QTc interval prolongation among patients with non-thyroid
cancer who were assigned vandetanib was calculated as 0.063–
0.427. This interval shows that at least 95% of the individual study
settings have an incidence of all-grade QTc interval prolongation
ranging from 6.3% to 42.7%.
The prevalence of borderline QTc interval prolongation ranged
from 14% to 15% during treatment of oncology patients observed
in a previous study, whereas arsenic trioxide, which can prolong
the QTc interval, was associated with an incidence of 68.8% [26–
29]. Some non-antiarrhythmic drugs such as cisapride [13] (a drug
used to treat gastroesophageal reflux) and terfenadine [30] are
often associated with a much higher incidence of QTc interval
prolongation. Compared with the incidence of other drugs that
cause a prolonged QTc interval, the incidence of all-grade QTc
interval prolongation associated with vandetanib is moderate.
The risk of drug-induced catastrophic ventricular arrhythmia is
of great interest to the FDA for the development of oncology
interventions. The most concerning issue is the incidence of TdP, a
polymorphic arrhythmia that can lead to sudden death. QTc
interval prolongation is one of the most important risk factors to
induce this life-threatening consequence. Much of the data on
treatment-induced TdP are derived from patients with congenital
long QT syndrome (LQTS), where the risk of TdP appears to be
greater if the QTc interval is .500 ms [31] (this would be defined
as high-grade QTc interval prolongation in our study). Intensive
monitoring and management of high-grade QTc interval
prolongation are crucial for patient safety. One patient observed
in a trial [14] that primarily concerned treatment of NSCLC
Figure 2. Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with non-
thyroid cancer who were assigned vandetanib.
doi:10.1371/journal.pone.0030353.g002
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uation of vandetanib. In future, the risks associated with
vandetanib should be weighed against its efficacy when vandetanib
is used in clinical practice.
Further exploratory analyses found a significant difference in
the incidence of vandetanib-associated high-grade QTc interval
prolongation (RR 3.24, 95% CI 1.57–6.71) between patients with
thyroid cancer and those with a non-thyroid malignancy. Thus,
clinicians and patients need to know that there are different risks
for different diseases.
On one hand, the variability in the incidence of high-grade QTc
interval prolongation in the different cancer types may be due to
variationsintreatmentduration. Themediantreatmentperiodfora
non-thyroid malignancy ranged from 1.8 to 3.0 months. However,
the median duration of thyroid cancer therapy was .18.8 months.
On the other hand, QTc interval prolongation has also been
detected in patients with hypothyroidism and subclinical hypo-
thyroidism (SH) [17,32,33], as well as in patients with high free
thyroxine levels and hyperthyroidism [34–36]. Some individuals
with thyroid cancer are more often associated with an abnormal
thyroid function [17,37], and are more prone to acquire prolonged
QTc intervals. When administering a drug that potentially
prolongs the QTc interval, thyroid cancer patients might be more
vulnerable to the severe side effects of the longer QTc interval
than those with a non-thyroid malignancy.
The analysis of data from the RCTs also revealed significant
5.70- and 7.26-fold increases in the Peto ORs of all-grade QTc
interval prolongation among patients with thyroid cancer and
those with non-thyroid malignancies, respectively, compared with
controls. The Peto ORs of high-grade QTc interval prolongation
were also assessed separately. There was a 3.48-fold increase in the
Peto OR for high-grade QTc interval prolongation among
patients with thyroid cancer. No difference was detected among
non-thyroid cancer patients. Nevertheless, the number of trials
eligible for evaluation of the risk of high-grade QTc interval
prolongation in these 2 cancer types was small and more trials
should be included to evaluate the true risk of high-grade QTc
interval prolongation in the future.
One of the strengths of the present meta-analysis is that we
quantitatively identified the incidence of QTc interval prolonga-
Figure 3. Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with
thyroid cancer who were assigned vandetanib.
doi:10.1371/journal.pone.0030353.g003
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vandetanib therapy for different cancers. Vandetanib was
approved by the FDA for the treatment of patients with advanced
MTC [5]. It has also been reported to be effective in the treatment
of other cancers [6,8,38]. Thus, it is worthwhile to devote
resources toward a detailed evaluation of its adverse effects
because it might be widely used in clinical practice. Besides, a
detailed analysis of the adverse effects would be warranted if the
information on potential harm appears to be essential for guiding
the decisions of clinicians, consumers, and policymakers. Many of
the RCTs in our study had extremely few patients that the data
were not reliable for detecting meaningful differences in the
incidence of adverse events. However, this meta-analysis com-
bined data from a number of trials and thus had greater statistical
reliability. Moreover, consistent results were found with respect to
the sensitivity analyses, and no evidence of publication bias was
found.
Our study considered the difference in the incidence of QTc
interval prolongation in association with both different cancer
types and treatment durations. It is nearly impossible to perform a
trial that primarily compares the different risks of one adverse
event between different cancers. However, it is useful for drug
agencies and doctors to determine the administration of this drug
in different diseases or for different treatment periods.
A limitation of this study is that the findings are not based on
individual patient data as those of many other meta-analyses are.
The trials included in our study might have underestimated the
incidence and RR of all-grade vandetanib-associated QTc interval
prolongation because of the use of different versions of adverse
event reporting criteria; the true incidence and RR might
therefore be higher. Some trials adopted CTCAE version 2 to
record adverse events, where a prolonged QTc interval was
identified when the QTc interval was .0.48 s. Other trials
employed CTCAE version 3, in which a prolonged QTc interval
was identified when the QTc interval was .0.45 s. The former
criterion is less strict when reporting QTc interval prolongation
and patients with QTc intervals ranging from 0.45 s to 0.48 s
would thus not have been recorded as having an adverse event
[16]. However, if we eliminate the trials that used CTCAE version
2 as a criterion, much of the information would be missed,
although we might obtain a higher incidence and RR. As for the
criteria for high-grade QTc interval prolongation in the 2 versions,
they are similar due to their clinical severity (that is, they require
treatment or have life-threatening consequences).
Figure 4. Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the
randomized controlled trials of patients with non-thyroid cancer.
doi:10.1371/journal.pone.0030353.g004
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vandetanib (300 mg/d) in this study. The risk at other doses or in
combination with other anticancer drugs was not evaluated.
Physicians should carefully interpret these results when they apply
them in clinical practice.
In conclusion, this study has shown that vandetanib is associated
with a significant increased risk of developing QTc interval
prolongation. The incidence of high-grade QTc interval prolon-
gation differs between thyroid cancer patients who require a
longer treatment duration and patients with non-thyroid malig-
nancies who require a shorter treatment period. The prolonged
QTc interval and other cardiac side effects of vandetanib require
thorough post-market surveillance and reporting.
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